Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

MilliporeSigma™ Calbiochem™ InSolution™ OM99-2 Available on GSA/VA Contract for Federal Government customers only.

An eight residue peptidomimetic, tight binding transition-state analog inhibitor of human brain memapsin 2.

Manufacturer:  MilliporeSigma™ 496000250UG

Catalog No. 49-600-0250UG

Add to cart



An eight residue peptidomimetic, tight binding transition-state analog inhibitor of human brain memapsin 2 (Ki = 1.6 nM, recombinant memapsin 2; Ki = 9.58 nM, recombinant pro-memapsin 2). Also inhibits cathepsin D (Ki = 48nM). This aspartyl protease inhibitor is designed from the template of the β-secretase site of Swedish β-amyloid precursor protein (APP) with Asp to Ala replacement; also includes a nonhydrolyzable hydroxyethylene isostere between Leu and Ala.

This product(s) resides on a Fisher Scientific GSA or VA contract. If you are viewing this page as a nonregistered user, the price(s) displayed is List Price. To view your GSA or VA contract pricing, log in using your account number, or become a registered user by contacting one of our Customer Service teams. You can also view your contract price by searching for this item(s) on GSA Advantage. To place an order, contact Fisher Scientific Customer Service.



A 1 mM (250μg in 280μl) solution in DMSO. Supplied as a trifluoroacetate salt.
90% by HPLC
Protect from Light
Protect from Moisture
human brain memapsin 2
Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit